Abstract
One hundred women with metastatic breast cancer (MBC) underwent high-dose chemotherapy with autologous stem cell rescue at our institution beginning in 1986. The patients underwent induction chemotherapy from June 1986 to December 1993. Patients who showed stable or responsive disease underwent HDC with cyclophosphamide (CY) at 7.5 g/m2 and thiotepa (TPA) at 675 mg/m2 or the same doses of CY and TPA with carmustine at 450 mg/m2. The source of stem cell rescue was either BM alone, BM and G-CSF-mobilized peripheral blood progenitor cells (PBPC) or PBPC alone if patients had BM involvement with MBC. With a median follow-up of 62 months (range 1–109 months), median survival from reinfusion was 16 months with a 5-year survival of 19 ± 4%. The median event-free survival (EFS) was 8 months with a 5-year EFS of 11 ± 3%. Patients achieving a complete response to induction therapy showed a higher 5-year EFS from reinfusion of 31 ± 8% in contrast to 3 ± 3% (P = 0.006) for patients who achieved a partial response to induction therapy prior to HDC. Marrow involvement or source of stem cell rescue did not affect outcome. Our mature results confirm that high-dose chemotherapy with autologous stem cell rescue can confer a prolonged DFS in a subset of women with MBC. However, the high rate of relapse remains a universally disturbing problem in this patient population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laport, G., Grad, G., Grinblatt, D. et al. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant 21, 127–132 (1998). https://doi.org/10.1038/sj.bmt.1701066
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701066
Keywords
This article is cited by
-
Stem-cell transplantation for the treatment of advanced solid tumors
Springer Seminars in Immunopathology (2004)
-
Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer
Bone Marrow Transplantation (2001)
-
High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome
Bone Marrow Transplantation (2000)